Quantum-Si prices $50M registered direct offering of common stock at $1.67
Securities Purchase Agreement: Quantum-Si has entered into a securities purchase agreement with an institutional investor to sell 29,940,119 shares of common stock at $1.67 per share, generating approximately $50 million in gross proceeds.
Offering Details: The closing of the offering is anticipated around July 8, 2025, pending customary closing conditions, with A.G.P./Alliance Global Partners serving as the sole placement agent.
Trade with 70% Backtested Accuracy
Analyst Views on QSI
About QSI
About the author
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Quantum-Si Grants 39,920 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Program: Quantum-Si has granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on December 20, 2026, with the remainder vesting in 12 equal quarterly installments, ensuring employees remain committed to the company, which promotes long-term retention.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thus mitigating potential compliance risks.
- Strategic Implications: By implementing this incentive measure, Quantum-Si not only enhances employee loyalty but also accelerates innovation and market expansion in the proteomics field by attracting high-quality talent.
Quantum-Si Grants 39,920 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Program: Quantum-Si has granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on December 20, 2026, with the remaining units vesting in 12 equal quarterly installments, ensuring that employees remain committed to the company over the long term.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, which enhances the transparency of the company's governance structure.
- Technological Transformation: Quantum-Si is redefining protein analysis through its benchtop platform, simplifying research workflows and accelerating proteomic discoveries, which is expected to drive innovation and market growth in the biotechnology sector.
Top Analysts Recommend Purchasing These 3 Penny Stocks Immediately
Investment Opportunities: Five-star Wall Street analysts have identified several penny stocks as Buys, suggesting significant potential gains from current price levels.
Quantum-Si (QSI): This biotechnology company focuses on protein sequencing technology, with a Buy rating and a price target of $4, indicating a potential upside of over 222%.
Opus Genetics (IRD): A clinical-stage biopharmaceutical company targeting eye disorders, it has a Buy rating and a price target of $6, suggesting an upside of more than 210%.
Dakota Gold Corp (DC): Engaged in mineral property exploration, particularly for gold, it has a Buy rating with a price target of $14, representing a potential upside of over 256%.
Quantum-Si to Showcase Major Advancements in Proteus™ Platform and Share Insights on Its Leading Technology Pipeline at Investor & Analyst Day
Investor & Analyst Day Announcement: Quantum-Si Incorporated is hosting an Investor & Analyst Day in New York City to present updates on its Proteus™ platform development, including a long-term technology roadmap and advancements in post-translational modification methods.
Proteus Platform Progress: The company has successfully completed over 50 sequencing runs on its prototype Proteus unit, achieving performance that meets or exceeds its current Platinum® Pro system, with plans for further optimization.
Amino Acid Detection: Quantum-Si has accelerated its path to detecting all 20 amino acids through collaborations and advanced computational tools, enhancing its capabilities in proteomics.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and product development, highlighting potential risks and uncertainties that could affect actual results.
Quantum-Si Highlights Ongoing Growth from Placement Initiatives and Milestones in Proteus Launch Amid Ongoing Market Challenges
Management Priorities and Financial Performance: CEO Jeffrey Hawkins outlined three key priorities for Quantum-Si: accelerating commercial adoption, delivering on innovation, and maintaining financial strength. The company reported Q3 2025 revenue of $552,000, impacted by capital sales headwinds, while CFO Jeffry Keyes noted a significant increase in operating expenses due to a lease termination.
Alternative Instrument Placement Program Success: The company has seen early success with its alternative instrument placement program, securing 12 new customers, primarily in academic labs, which have begun making initial reagent purchases despite NIH funding challenges.
Proteus System Milestone and Product Launch: Quantum-Si achieved a significant milestone by successfully completing sequencing runs on its prototype Proteus system and launched its version 4 sequencing kit, which enhances amino acid detection capabilities.
Outlook and Analyst Sentiment: Management remains cautiously optimistic about the long-term market opportunity in proteomics, despite ongoing capital market headwinds and NIH funding uncertainties. Analysts expressed concerns about funding delays and the pace of adoption, while management emphasized tight cost controls and strategic milestones.
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
Quantum-Si Grants 39,920 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Program: Quantum-Si has granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on December 20, 2026, with the remainder vesting in 12 equal quarterly installments, ensuring employees remain committed to the company, which promotes long-term retention.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, thus mitigating potential compliance risks.
- Strategic Implications: By implementing this incentive measure, Quantum-Si not only enhances employee loyalty but also accelerates innovation and market expansion in the proteomics field by attracting high-quality talent.
Quantum-Si Grants 39,920 RSUs to New Employees Under 2023 Inducement Plan
- Employee Incentive Program: Quantum-Si has granted 39,920 restricted stock units (RSUs) to new employees under the 2023 Inducement Equity Incentive Plan, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in protein analysis.
- Vesting Conditions: The RSUs will vest 25% on December 20, 2026, with the remaining units vesting in 12 equal quarterly installments, ensuring that employees remain committed to the company over the long term.
- Compliance Assurance: This grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring Quantum-Si adheres to relevant regulations while attracting new employees, which enhances the transparency of the company's governance structure.
- Technological Transformation: Quantum-Si is redefining protein analysis through its benchtop platform, simplifying research workflows and accelerating proteomic discoveries, which is expected to drive innovation and market growth in the biotechnology sector.
Top Analysts Recommend Purchasing These 3 Penny Stocks Immediately
Investment Opportunities: Five-star Wall Street analysts have identified several penny stocks as Buys, suggesting significant potential gains from current price levels.
Quantum-Si (QSI): This biotechnology company focuses on protein sequencing technology, with a Buy rating and a price target of $4, indicating a potential upside of over 222%.
Opus Genetics (IRD): A clinical-stage biopharmaceutical company targeting eye disorders, it has a Buy rating and a price target of $6, suggesting an upside of more than 210%.
Dakota Gold Corp (DC): Engaged in mineral property exploration, particularly for gold, it has a Buy rating with a price target of $14, representing a potential upside of over 256%.
Quantum-Si to Showcase Major Advancements in Proteus™ Platform and Share Insights on Its Leading Technology Pipeline at Investor & Analyst Day
Investor & Analyst Day Announcement: Quantum-Si Incorporated is hosting an Investor & Analyst Day in New York City to present updates on its Proteus™ platform development, including a long-term technology roadmap and advancements in post-translational modification methods.
Proteus Platform Progress: The company has successfully completed over 50 sequencing runs on its prototype Proteus unit, achieving performance that meets or exceeds its current Platinum® Pro system, with plans for further optimization.
Amino Acid Detection: Quantum-Si has accelerated its path to detecting all 20 amino acids through collaborations and advanced computational tools, enhancing its capabilities in proteomics.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and product development, highlighting potential risks and uncertainties that could affect actual results.
Quantum-Si Highlights Ongoing Growth from Placement Initiatives and Milestones in Proteus Launch Amid Ongoing Market Challenges
Management Priorities and Financial Performance: CEO Jeffrey Hawkins outlined three key priorities for Quantum-Si: accelerating commercial adoption, delivering on innovation, and maintaining financial strength. The company reported Q3 2025 revenue of $552,000, impacted by capital sales headwinds, while CFO Jeffry Keyes noted a significant increase in operating expenses due to a lease termination.
Alternative Instrument Placement Program Success: The company has seen early success with its alternative instrument placement program, securing 12 new customers, primarily in academic labs, which have begun making initial reagent purchases despite NIH funding challenges.
Proteus System Milestone and Product Launch: Quantum-Si achieved a significant milestone by successfully completing sequencing runs on its prototype Proteus system and launched its version 4 sequencing kit, which enhances amino acid detection capabilities.
Outlook and Analyst Sentiment: Management remains cautiously optimistic about the long-term market opportunity in proteomics, despite ongoing capital market headwinds and NIH funding uncertainties. Analysts expressed concerns about funding delays and the pace of adoption, while management emphasized tight cost controls and strategic milestones.
